RedHill Biopharma (RDHL) Change in Cash (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Change in Cash data on file, last reported at $4.8 million in Q4 2022.

• Change in Cash for Q4 2022 came in at $4.8 million, down 23.04% year-over-year; the trailing twelve-month figure through Dec 2022 was -$9.4 million (down 3516.67% YoY), and the FY2025 annual result was -$644000.0, up 32.99% from the prior year.
• Change in Cash grew to $4.8 million in Q4 2022 per RDHL's latest filing, from -$11.8 million in the prior quarter.
• Over five years, Change in Cash peaked at $52.5 million in Q1 2020 and troughed at -$59.4 million in Q2 2020.
• A 5-year average of $178300.0 and a median of $1.0 million in 2019 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2020 and 2021: Change in Cash jumped 973.31% in 2020, then plunged 821.02% in 2021.
• A 5-year view of Change in Cash shows it stood at $10.3 million in 2018, then surged by 67.7% to $17.3 million in 2019, then tumbled by 82.19% to $3.1 million in 2020, then jumped by 101.13% to $6.2 million in 2021, then declined by 23.04% to $4.8 million in 2022.
• Business Quant data shows RDHL's Change in Cash at $4.8 million in Q4 2022, -$11.8 million in Q3 2022, and -$1.8 million in Q2 2022.